## VPA10491/005/003

## Cephacare flavour 500 mg tablets for dogs

Variation	Summary	Date
Vet - B32	VNRA - Vet - B32 - Change in the specification parameters or limits of the finished product to describe more accurately the appearance of the product - B32 Changes to the quality part of the dossier: Change in the specification parameters or limits of the finished product to describe more accurately the appearance of the product	26/03/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	12/10/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	12/10/23
Vet - B3 n)	VNRA - Vet - B3 n) - n) Deletion of a non-significant specification parameter (finished product) - B3 n) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) in the specification parameters or limits of the finished product	11/10/23
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuiring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	27/03/23
Vet - C10 a)	VNRA - Vet - C10 a) - a) Administrative information concerning the holder's representative - C10 a) Changes to the safety, efficacy and pharmacovigilance part of the dossier: Changes to the labelling or the package leaflet which shall not be connected with the SPC: — administrative information concerning the holder's representative	08/06/22
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - G.I.15 z) Safety, Efficacy, Pharmacovigilance changes - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g.	23/05/22

	variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
	II - B.II.d.1.e - e) Change outside the approved specifications	
	limits range - B.II.d.1.e - QUALITY CHANGES - FINISHED	
B.II.d.1.e	PRODUCT - Control of finished product - Change in the	25/04/22
	specification parameters and/or limits of the finished product -	
	Change outside the approved specifications limits range	